The gut microbiome comprises the trillions of bacteria and other microorganisms that live in our digestive tracts, and it has ...

A new study found no significant benefit in adding low-dose oral glucocorticoids to immunosuppressive therapy for improving ...

USE of the Apollo wearable for 4 weeks improved fatigue, Raynaud phenomenon symptoms, and quality of life in patients with ...

The following is a summary of “Cross-trait GWAS in COVID-19 and systemic sclerosis reveals novel genes implicated in fibrotic ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development ...

Health charity Scleroderma & Raynaud's UK (SRUK) is urging the public to take a 60-second online test to find out if they may ...

umcutrecht.nl Objectives Systemic sclerosis (SSc) is an autoimmune disease with unknown pathogenesis manifested by inflammation, vasculopathy and fibrosis in skin and internal organs. Type I ...

“Broken skin barriers” are real. They’re the subject of great interest from " skinfluencers " on TikTok, but they’re also ...

Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis (lcSSc), with patients having a high IFN activity presenting worse clinical outcomes.

The mechanisms that drive the diverse disease manifestations and increased cancer risk associated with systemic sclerosis are unclear. Investigating the genomic alterations observed in patients ...

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not.